Trials / Completed
CompletedNCT01356680
HD17 for Intermediate Stage Hodgkin Lymphoma
HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,100 (actual)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone) | |
| DRUG | ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) | |
| RADIATION | 30Gy IF-RT (Involved-Field Radiotherapy) | |
| RADIATION | 30Gy IN-RT (Involved-Node Radiotherapy) |
Timeline
- Start date
- 2012-01-13
- Primary completion
- 2020-03-21
- Completion
- 2020-03-23
- First posted
- 2011-05-19
- Last updated
- 2020-04-06
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01356680. Inclusion in this directory is not an endorsement.